Skip to main
VSTM

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Verastem is a promising investment opportunity in the biopharmaceutical industry, with a strong pipeline and potential for success in the treatment of various cancers. The company's lead drug candidate, VS-7475, has shown positive results in trials for pancreatic, lung, and colorectal cancers, with manageable side effects. Additionally, Verastem has a partnership model in place for commercialization in the EU which indicates a solid revenue stream in the future. With a focus on developing innovative and effective treatments for cancer patients, Verastem is poised for growth and success in the coming years.

Bears say

Verastem is facing a critical challenge in increasing the efficacy of its main drug, VS-7375, as a potential G12D backbone for multiple tumor types. With recent clinical data showing stronger pharmacologic and dose-dependent activity at the 900 mg QD dose, the company's benchmark in previously treated PDAC is becoming more defined and highly competitive. However, the next step in demonstrating biomarker response and durable disease control, along with maintaining a favorable safety profile, will be crucial for the drug to stand out in the crowded oncology market.

Verastem (VSTM) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Verastem (VSTM) has a Strong Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.